| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 1B | -3% |
| Gross Profit | 519MM | - |
| Cost Of Revenue | 516MM | +6% |
| Operating Income | -127MM | -88% |
| Operating Expenses | 646MM | - |
| Net Income | -141MM | -87% |
| R&D | 79MM | -8% |
| G&A | 292MM | -7% |
| Amortization | 138MM | -1% |
| Interest Expense | 67MM | -7% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Beyond analysts' top -and-bottom-line estimates for Elanco Animal Health (ELAN), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.
Launches first-ever tracking site for often-fatal parvovirus outbreaks to Save 1 Million Puppies by 2030 GREENFIELD, IN / ACCESSWIRE / April 23, 2024 / Elanco Animal Health Incorporated (NYSE:ELAN) today unleashed a multi-faceted educational campaign ...
In this piece, we will take a look at the 13 best low price pharma stocks to invest in. If you want to skip our overview of the pharma industry and want to skip to the five top low price stocks in this list, then you can skip ahead to 5 Best Low Price Pharma […]
Elanco Animal Health Incorporated (NYSE: ELAN) will announce its first quarter 2024 financial results on Wednesday, May 8, 2024. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance.
Elanco Animal Health said on Monday that it had appointed two new directors to its board after reaching an agreement with activist investor Ancora Holdings but stopped short of naming a new CEO. The company that makes medicines and vaccinations for pets and livestock said it has added Kathy Turner and Craig Wallace to the board of directors. that it wanted four board seats at Elanco and to replace CEO Jeffrey Simmons over "poor performance."
Elanco Animal Health Incorporated (NYSE: ELAN) today announced that it has appointed two new independent directors, Kathy Turner and Craig Wallace, to its Board of Directors (the "Board"), effective immediately, expanding the Board to 14 members.
Investment firm Ancora Holdings has reached an agreement with Elanco Animal Health to add two of its director candidates to the company's board, Bloomberg News reported late on Sunday, citing people with knowledge of the matter. Elanco, which makes medicines and vaccinations for pets and livestock will add Ancora nominees Craig Wallace and Kathy Turner to its board of directors, the report said. However, Elanco CEO Jeff Simmons will retain his position, the report added.
Elanco Animal Health Inc (NYSE:ELAN), a company specializing in the development, manufacturing, and marketing of products for animal health and production, has reported an insider purchase filed with the SEC.
NORTHAMPTON, MA / ACCESSWIRE / March 5, 2024 / Elanco Animal Health CEO, Jeff Simmons joins Jim Cramer on Mad Money to discuss the company's commitment to create solutions for farmers and ranchers that can reduce, measure, and monetize greenhouse ...
Elanco Animal Health (NYSE: ELAN) announced today the appointment of Shiv O'Neill as the company's Executive Vice President, General Counsel and Corporate Secretary. O'Neill will be responsible for the global strategy and operations of the Company's legal team, ethics & compliance organization and ESG efforts.